Medindia

X

OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer

Friday, June 6, 2008 General News J E 4
Advertisement
SAN FRANCISCO, June 6 OxyBand Technologies Inc., SanFrancisco, has hired Dr. Olivier Postel to lead the company's bio-medicaltechnology development and expand the company's intellectual propertyportfolio. OxyBand develops innovative therapeutic gas technology for health,cosmetic and consumer care. The company's inaugural device is an oxygen woundhealing dressing, cleared by the FDA for medical and over the countermarketing. OxyBand has received a contract from the US Army.

The extensive experience Dr. Postel brings with him as Chief TechnologyOfficer will help to focus the company's efforts in research and development,manufacturing and marketing toward launching new products in the market place.

Prior to joining OxyBand, Dr. Postel was the Director of ProcessEngineering and Integration at dpiX, the world leader of sensor arrays for X-ray medical imaging, where among his other responsibilities, he lead theengineering start-up of a $100 MM expansion facility in Colorado Springs,supported by four global medical equipment companies, Varian Medical Systems,Phillips Medical Systems, Siemens A.G. and Thales.

Dr. Postel has an extensive background in space propulsion systems and gaschemistry, beginning his career as a Staff Scientist at Stanford University'sPlasma Propulsion Lab. He later leveraged his expertise in these fields andfounded a medical device start up in Cold Plasma device technology forcosmetic and wound care funded in part by NIH. Dr. Postel has served on an NIHreview committee on Infectious Diseases and Microbiology for the past severalyears. Dr. Postel has also worked with other Silicon Valley start-ups ofvarious stages in developing technology.

The market is ready for OxyBand's innovative technology solutions. Dr.Postel's addition to the OxyBand team will help the company to become a marketleader.

"We are very pleased Olivier has joined our team and we hope to capitalizeon his expertise in therapeutic gas science and technology, and productdevelopment to enter the market quickly," said Dr. Amie Franklin, CEO ofOxyBand Technologies. OxyBand is presently raising additional funding tosupport new product development and to launch the company's first FDA cleareddevice.

"I am excited about the strategic intellectual property position and Ihope to help to revolutionize the fields of wound care treatment anddiagnostics," said Dr. Postel. "In addition, as a member of the OxyBand team Ilook forward to working with the United States Institute For Surgical Researchin providing superior wound care for the men and women serving in themilitary."

Dr. Postel holds MS degrees in Materials Sciences and Solid StateChemistry from France and a PhD in Mechanical Engineering from the Universityof Minnesota. As part of his research funded by NASA on the use of spacecraftpropulsion arcjet thrusters, he received an innovation award by the aerospaceagency.

About OxyBand Technologies, Inc.

OxyBand Technologies Inc. is a bio-medical technology company thatdevelops and manufactures therapeutic gas technology for the treatment ofhealth, cosmetic and consumer care. The company has an intellectual propertyportfolio of proprietary products and the first pure oxygen wound dressing,OxyBand(TM) cleared by the FDA for medical and over the counter marketing. Theproprietary portfolio is poised to set a new standard of care to the market.

For additional information about OxyBand please contact OxyBandTechnologies Inc. at information@oxyband.com or at 415 283 3356.

SOURCE OxyBand Technologies Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
GlaxoSmithKline Acquires Sirtris Pharmaceuticals, ...
S
Sangamo BioSciences Provides Update on Diabetic Ne...